Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


LifeCycle Pharma signs exclusive license agreement with Sciele Pharma
to market a new formulation of fenofibrate in 120mg and 40mg dosage strengths

Summary: LifeCycle Pharma announces US partnership with Sciele Pharma for LCP-FenoChol and also enters into Technology Partnership for MeltDose® Technology

LifeCycle Pharma A/S (OMX: LCP) today announced that it has signed an exclusive license agreement with Sciele Pharma, Inc. (NASDAQ:SCRX) to market fenofibrate in the US, Canada, and Mexico, in 120 milligram and 40 milligram strengths. Fenofibrate is prescribed for the treatment of hyperlipidemia and triglyceridemia. Under the terms of the agreement, LifeCycle Pharma will receive an up-front payment of US$5 million, milestone payments of up to US$12 million upon FDA approval and meeting certain sales targets, and tiered mid-teen to high-teen royalty payments on product sales.

LifeCycle Pharma filed with the US Food and Drug Administration (FDA) in October 2006 a New Drug Application (NDA) 505(b)(2) for this new formulation of fenofibrate (LCP-FenoChol). Upon FDA approval, this new formulation of fenofibrate in 120 mg. and 40 mg. dosage strengths are expected to be the lowest doses of fenofibrate available for patients.

Sciele has also entered into a technology collaboration with LifeCycle Pharma utilizing LifeCyle’s MeltDose Technology for the life-cycle management of its products. Under the terms of this agreement, LifeCycle Pharma will be responsible for the development of the product and in return, LifeCycle Pharma will be entitled to receive R&D reimbursement, development milestones and mid-single digit royalties on eventual sales.

Patrick Fourteau, Chief Executive Officer of Sciele, said, “This agreement, coupled with our existing Triglide product line and our pravastatin/fenofibrate combination in phase III clinical trials, will help us to build a strong position in the fast growing fenofibrate market. Furthermore, this collaboration will enable us to capitalize on LifeCycle Pharma’s proprietary MeltDose technology to further expand our product pipeline through life-cycle management.”

Dr. Flemming Ornskov, CEO of LifeCycle Pharma stated, “We are extremely pleased with both of these agreements, and look forward to Sciele helping us capitalize on LCP-FenoChol’s (fenofibrate) significant commercial opportunity of being the lowest dose fenofibrate product in the US$1.3 billion US fenofibrate market. Sciele has a proven track record in the cardiovascular market with its Primary Care sales force.

For further information please contact:
LifeCycle Pharma A/S
Flemming Ornskov
President & CEO
DK Tel. +45 24 20 03 68
US Tel. +1 917 288 6446

About LifeCycle Pharma A/S:
LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging pharmaceutical company with a broad and late stage product pipeline in therapeutic areas of cholesterol management, hypertension and organ transplant. LifeCycle Pharma’s product candidates are proprietary and designed to improve the quality of existing drugs by enhancing the release and absorption of drugs in the human body. LifeCycle Pharma’s proprietary technology platform, MeltDose® technology, offers lower dosing, reduced side effects and improved safety and patient compliance, as well as reduced product development time and production costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under the trading symbol (LCP). Please visit for further information about LifeCycle Pharma A/S.

About Sciele Pharma, Inc. :
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes and Women's Health. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes, and its Women's Health products are designed to improve the health and well-being of women and mothers and their babies. Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 80

Publisher Contact Information:

LifeCycle Pharma A/S
+45 24 20 03 68

Company profile of LifeCycle Pharma A/S
Past press releases of LifeCycle Pharma A/S.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.